Payment overview · 2025
General Payments
$1,258.92
84 reported records · 12 companies
Healthcare provider profile · identity verified
Radit Aur, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LONG BEACH, CA · NPI 1255748596
Verified facts
What the public records show
CMS Open Payments records show Radit Aur, PA-C received $1,258.92 in general payments during 2025 across 84 reported records.
Amgen Inc. accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $305.80 | 24.3% | 38 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $267.68 | 21.3% | 18 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $237.05 | 18.8% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.00 | 7.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $89.37 | 7.1% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $57.59 | 4.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.15 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.60 | 3.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.22 | 2.6% | 2 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $27.32 | 2.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $23.57 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.57 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,258.92 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $305.80 | 38 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $270.04 | 34 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $217.56 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $152.84 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.00 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.46 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $89.37 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $89.37 | 5 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $57.59 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $53.15 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $45.60 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 276 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
276 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
276 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 747 | 177 |
| Losartan Potassium | Losartan Potassium | 459 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 387 | 87 |
| Metformin Hcl | Metformin Hcl | 370 | 90 |
| Gabapentin | Gabapentin | 295 | 57 |
| Jardiance | Empagliflozin | 276 | 49 |
| Famotidine | Famotidine | 254 | 45 |
| Omeprazole | Omeprazole | 239 | 59 |
| Celecoxib | Celecoxib | 238 | 60 |
| Ibuprofen | Ibuprofen | 183 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 177 | 39 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 142 | 41 |
| Meclizine Hcl | Meclizine Hcl | 142 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 141 | 37 |
| Lisinopril | Lisinopril | 141 | 30 |
| Baclofen | Baclofen | 135 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 28 |
| Ozempic | Semaglutide | 120 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 112 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 24 |
| Alendronate Sodium | Alendronate Sodium | 110 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 25 |
| Azithromycin | Azithromycin | 106 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 33 |
| Naproxen | Naproxen | 89 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 12 |
| Verapamil Er | Verapamil Hcl | 80 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 18 |
| Buspirone Hcl | Buspirone Hcl | 70 | 15 |
| Amoxicillin | Amoxicillin | 69 | 45 |
| Mirtazapine | Mirtazapine | 67 | 18 |
| Propranolol Hcl | Propranolol Hcl | 67 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 18 |
| Azelastine Hcl | Azelastine Hcl | 63 | 13 |
| Glipizide | Glipizide | 59 | 13 |
| Cephalexin | Cephalexin | 58 | 31 |
| Rybelsus | Semaglutide | 56 | suppressed |
| Repatha Sureclick | Evolocumab | 55 | 11 |
| Furosemide | Furosemide | 54 | 14 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 53 | suppressed |
| Trulicity | Dulaglutide | 51 | 11 |
| Nateglinide | Nateglinide | 49 | 11 |
| Allopurinol | Allopurinol | 48 | suppressed |
| Carvedilol | Carvedilol | 46 | 12 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 45 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 42 | 11 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Simvastatin | Simvastatin | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 11 |
| Mupirocin | Mupirocin | 38 | 23 |
| Spironolactone | Spironolactone | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 34 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 11 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 27 | 11 |
| Atenolol | Atenolol | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Enulose | Lactulose | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Prednisone | Prednisone | 13 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,258.92 · 84 records | Amgen Inc. | APTIMA, CAPVAXIVE, Fibroscan, GARDASIL 9, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, REPATHA, THINPREP 2000 PROCESSOR, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, WaveWriter Alpha Prime 16, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error